CDK Inhibitors Management

Adverse event management for CDK inhibitors in hormone receptor positive breast cancer

CDK 4/6 inhibitors have transformed the treatment landscape for patients with early and metastatic hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer, offering significant improvements in progression-free survival and overall outcomes, especially when combined with hormone therapy. Despite their demonstrated efficacy, these therapies can be associated with treatment-related adverse events, including gastrointestinal (GI) symptoms, neutropenia, and anemia, which require careful management to ensure adherence and preserve quality of life. Managing these therapies comes with challenges, particularly in the community setting where the majority of patients receive their care. Clinicians must navigate the evolving landscape of HR+ breast cancer while ensuring tolerability, adherence, and optimal outcomes.

This program aims to provide oncology professionals with evidence-based strategies to optimize the use of CDK 4/6 inhibitors across the breast cancer continuum. By addressing both early and metastatic disease settings, the program emphasizes the importance of dose adjustments to manage adverse events effectively without compromising efficacy. It also highlights the critical role of multidisciplinary care coordination in balancing patient outcomes with quality of life.

Tailored for oncology clinicians, the program offers practical insights to enhance patient care through proactive management of treatment-related side effects, streamlined care coordination, and comprehensive patient and caregiver education.

Objectives

• Outline strategies to evaluate patients with early stage and metastatic HR+ HER2- breast cancer receiving CDK inhibitors and manage potential treatment-related AEs.
• Review care coordination strategies within the multidisciplinary cancer care team, aimed at balancing quality of life and outcomes in early stage and metastatic HR+ HER2- breast cancer.
• Provide guidance on AE management and on the efficacy of CDK inhibitors while addressing the associated AEs.

Featured Resources

Adverse Event Management for CDK Inhibitors in Hormone Receptor–Positive Breast Cancer

Learn how CDK inhibitors can help manage hormone receptor-positive breast cancer by targeting overactive proteins that drive uncontrolled cell growth. Explore this comprehensive infographic  with essentials like dosage recommendations, potential side effects, and how to consult patients with breast cancer on managing their symptoms for effective therapy management.
Download Infographic

SPOTLIGHT ON MIAMI CANCER INSTITUTE: The Role of a Breast Cancer Clinical Pharmacy Specialist for CDK4/6 Inhibitor Management

This spotlight examines the dynamic role of a clinical pharmacy specialist at Miami Cancer Institute (MCI), part of Baptist Health South Florida, in the management of patients with breast cancer treated with oral therapies such as CDK4/6 inhibitors. MCI operates within a hybrid academic-community care model, offering access to subspecialized clinicians, clinical researchers, and genomic scientists, many of whom bring experience from leading cancer centers nationwide.
Download Program Spotlight

Podcasts

Stay Ahead of the Curve on CDK4/6 Inhibitor Toxicities – [Mini Podcast] Ep. 201

Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle and dietary techniques to improve tolerance of this treatment.
Listen to Podcast

Contact Us

For more information on this project, please contact the ACCC Provider Education department.